Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertensionopen access
- Authors
- Sung, Ki-Chul; Hong, Soon Jun; Rhee, Moo-Yong; Jeong, Myung-Ho; Kim, Dae-Hee; Lim, Sang-Wook; Park, Kyungil; Lee, Jin Bae; Kim, Seok-Yeon; Cho, Jin-Man; Cho, Goo-Yeong; Heo, Jung-Ho; Kim, Sang-Hyun; Lee, Hae-Young; Kim, Weon; Cho, Deok-Kyu; Park, Sungha; Shin, Jinho; Pyun, Wook-Bum; Kwon, Kihwan; Rha, Seung-Woon; Jung, Jin-A
- Issue Date
- Apr-2023
- Publisher
- WILEY
- Keywords
- combination therapy; hypertension; low-dose
- Citation
- JOURNAL OF CLINICAL HYPERTENSION, v.25, no.5, pp.429 - 439
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL HYPERTENSION
- Volume
- 25
- Number
- 5
- Start Page
- 429
- End Page
- 439
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186383
- DOI
- 10.1111/jch.14656
- ISSN
- 1524-6175
- Abstract
- We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.